Premium
Pharmacokinetic comparison of two carbamazepine slow‐release formulations
Author(s) -
Jensen P. K.,
Møller A.,
Gram L.,
Jensen N. O.,
Dam M.
Publication year - 1990
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1990.tb01603.x
Subject(s) - cmin , carbamazepine , cmax , pharmacokinetics , regimen , pharmacology , medicine , epilepsy , psychiatry
In a single‐blind pharmacokinetic study patients being treated with conventional carbamazepine (CBZ) in a t.i.d. regimen were randomly allocated to identical doses of two CBZ slow‐release formulations (Trimonil Retard® and Tegretol Retard®) administered once daily. Statistical analysis involved the following parameters: AUC, Cmin, Cmax and Fluctuation Index (FI). With regard to Cmin and FI statistically significant differences in favour of Tegretol Retard® were observed.